Author

Akira Kitani

Observed name: A. Kitani

Institution: Seirei Sakura Citizen Hospital

Observed institutions: Seirei Sakura Citizen Hospital, Saitama Medical Center, Saitama Medical University, Sagara Hospital, Tokyo Kyosai Hospital, Saitama Medical University

ORCID: 0000-0003-1781-373X

Observed ORCID: 0000-0003-1781-373X

OpenAlex ID: A5078032376

Evaluation of quality of life and psychological response in cancer patients treated with radiotherapy

2008 · Takeo Takahashi, Mikito Hondo, et al. · Radiation Medicine · 95

CYP2D6 Genotype–Guided Tamoxifen Dosing in Hormone Receptor–Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

2019 · Kenji Tamura, Chiyo K. Imamura, et al. · Journal of Clinical Oncology · 34

Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2− Early-stage Breast Cancer

2018 · Takashi Kuwayama, Seigo Nakamura, et al. · Clinical Breast Cancer · 32

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis

2017 · Naoki Niikura, Akihiko Shimomura, et al. · Breast Cancer Research and Treatment · 29

Increased pain after palliative radiotherapy: not only due to cancer progression

2024 · Satoshi Murakami, Akira Kitani, et al. · Annals of Palliative Medicine · 3

A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.

2018 · Toshimi Takano, Chiyo K. Imamura, et al. · Journal of Clinical Oncology · 2

Primary analysis of a randomized phase II, multicenter trial: Neoadjuvant weekly nab-paclitaxel 100mg/m2 followed by FE100C compared with docetaxel 75mg/m2 followed by FE100C for early breast cancer in Japan.

2015 · Takashi Kuwayama, Hideko Yamauchi, et al. · Journal of Clinical Oncology · 2

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase 2 Study

2019 · Kenji Tamura, Chiyo K. Imamura, et al. · SSRN Electronic Journal · 1

Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis

2017 · A. Shimomura, N. Niikura, et al. · Annals of Oncology · 1

Gefapixant Citrate, a Selective P2X3 Receptor Antagonist, May Improve Cancer-Related Hypergeusia: A Case Report

2025 · Satoshi Murakami, Kazutaka Yamagishi, et al. · Journal of Palliative Medicine

Comparison of dose-dense versus standard neoadjuvant chemotherapy for HER2 negative breast cancer: Retrospective, multicenter, real-world, Japanese study (JONIE5).

2025 · Kaori Terata, Masanori Oshi, et al. · Journal of Clinical Oncology

A Retrospective Cohort Study to Investigate Association between Preferences for Future Care and Period of Final Chemotherapy Administration before End-of-Life

2017 · Sena Yamamoto, Keiko Eguchi, et al. · The Breast

An evaluation of novel antineoplastic agent on prostate cancer

2003 · Parker Johnson, Akira Kitani · Atlanta University Center Robert W. Woodruff Library (Atlanta University Center Robert W. Woodruff Library)

Works count: 13

Citation count: 199

H-index: 4

I10-index: 4